Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Last Updated: June 29, 2022

Details for Patent: RE46965

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE46965 protect, and when does it expire?

Patent RE46965 protects HALAVEN and is included in one NDA.

This patent has thirty-eight patent family members in fourteen countries.

Summary for Patent: RE46965

Title:	Intermediates for the preparation of analogs of Halichondrin B
Abstract:	The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4). ##STR00001##
Inventor(s):	Austad; Brian (Tewksbury, MA), Chase; Charles E. (Londonderry, NH), Fang; Francis G. (Andover, MA), Calkins; Trevor (Stoughton, WI), Lewis; Bryan M. (North Brunswick, NJ)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	13/924,892
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent RE46965

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE46965

PCT Information
PCT Filed	June 03, 2005	PCT Application Number:	PCT/US2005/019669
PCT Publication Date:	December 15, 2005	PCT Publication Number:	WO2005/118565

International Family Members for US Patent RE46965

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005250487	See Plans and Pricing
Canada	2567984	See Plans and Pricing
Canada	2822994	See Plans and Pricing
Canada	2935786	See Plans and Pricing
Canada	3028453	See Plans and Pricing
China	101899026	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

AstraZeneca

Dow

McKinsey

Harvard Business School

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.